Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial

Zydus Therapeutics reported that its investigational drug saroglitazar achieved resolution of steatohepatitis without worsening of fibrosis in 39.1% of patients receiving the 4 mg…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.cnbctv18.com)